Endometrial stromal sarcoma with intracaval extension at initial presentation.

Endometrial stromal sarcoma (ESS) is a rare uterine neoplasm. Tumor involvement of the large vessels is extremely rare. This is a case report of ESS with tumor invasion of the inferior vena cava at initial presentation.

Oncology treatment improvement--our experience in Serbia.

OBJECTIVES: To determine weather structural changes by a tumor board made any difference in quality of treatment for oncology patients. MATERIAL AND METHOD: Current management of our hospital initiated structural changes in the tumor board in January 2010 and improvement was measured through comparing the clinical staging of cervical cancer to previous tumor board results. RESULTS: 365 patients were seen by a multidisciplinary tumor board from January to December of 2010. There were 146 cases of cervical cancer. 87 were staged as Ib-IIa for radical surgery, 59 patients were staged as advanced stage of disease and RT was proposed as well as combined radio-chemotherapy in some cases. CONCLUSION: Structural changes in the tumor board have made a significant improvement in the oncology care of our patients, primarily because of a multidisciplinary approach to gynecological malignancies and additional imaging performed in all cases of cervical cancer for better insight in the spread of the disease.

Synchronous primary tumors: appendiceal and ovarian cancer--case report.

A 64-year-old women was operated on for acute abdomen and both appendiceal and ovarian tumors were found. Histology revealed synchronous adenocarcinoma of the appendix and serous pappillary carcinoma of the right ovary. The patient was given adjuvant chemotherapy and received six cycles of cisplatinum. Regular follow-up showed no recurrence of the two synchronous primary tumors. A rare case of synchronous primary tumors of appendiceal and ovarian origin is reported. The tumors proved to be difficult to treat requiring several combined medical therapies, including surgery, chemo- and radiotherapy.

Cold-knife conization versus the loop electrosurgical excision procedure for treatment of cervical dysplasia.

INTRODUCTION: Classical conization is a standard procedure for treatment of cervical lesions. Conization with loop diathermy is well established and lesions can be excised in more than 90% of cases. OBJECTIVE: To compare two methods of conization for the treatment of cervical dysplasia. METHOD: The study included 172 patients who had conization for diagnosed cervical dysplasia. A retrospective analysis was conducted on incidence of complications and presence of dysplasia on the specimen edges after classical conization compared to conization with loop diathermy. The possibilities for analyzing specimen edges were reviewed. RESULTS: A significantly higher incidence of complications was found among patients who underwent classical conization compared to those who had the loop diathermy procedure. The loop procedure is sufficient for treatment of cervical dysplasias. CONCLUSION: The authors suggest loop diathermy conization as the method of choice for treatment of cervical dysplasia.

Solitary ovarian mass: a case of metastatic malignant melanoma.

Malignant melanoma involving the ovaries is rare and in most cases metastatic in origin. We present a case of ovarian malignant melanoma presenting as a large adnexal mass in a patient with no previous history of malignant melanoma.

Molecular profiling of cervical cancer progression.

Most cancer patients die of metastatic or recurrent disease, hence the importance to identify target genes upregulated in these lesions. Although a variety of gene signatures associated with metastasis or poor prognosis have been identified in various cancer types, it remains a critical problem to identify key genes as candidate therapeutic targets in metastatic or recurrent cancer. The aim of our study was to identify genes consistently upregulated in both lymph node micrometastases and recurrent tumours compared to matched primary tumours in human cervical cancer. Taqman Low-Density Arrays were used to analyse matched tumour samples, obtained after laser-capture microdissection of tumour cell islands for the expression of 96 genes known to be involved in tumour progression. Immunohistochemistry was performed for a panel of up- and downregulated genes. In lymph node micrometastases, most genes were downregulated or showed expressions equal to the levels found in primary tumours. In more than 50% of lymph node micrometastases studied, eight genes (AKT, BCL2, CSFR1, EGFR1, FGF1, MMP3, MMP9 and TGF-beta) were upregulated at least two-fold. Some of these genes (AKT and MMP3) are key regulators of epithelial-mesenchymal transition in cancer. In recurrent tumours, almost all genes were upregulated when compared to the expression profiles of the matched primary tumours, possibly reflecting their aggressive biological behaviour. The two genes showing a consistent downregulated expression in almost all lymph node metastases and recurrent tumours were BAX and APC. As treatment strategies are very limited for metastatic and recurrent cervical cancer, the upregulated genes identified in this study are potential targets for new molecular treatment strategies in metastatic or recurrent cervical cancer.

Survival rate and prognostic factors for patients who underwent surgical procedures for invasive carcinoma of the vulva in Serbia.

OBJECTIVES: To determine five-year survival rate and prognostic factors for patients who underwent radical surgery for carcinoma of the vulva. MATERIAL AND METHOD: 94 women were operated on from 1989 to 1996 at the Clinical Centre of Serbia. RESULTS: Five-year survival was 78.56% for Stage I, 73.5% for Stage II, for Stage III--14.28%, and for Stage IV--7.14%. Five-year survival rate for tumor size between 2 cm and 5 cm was 57.14%, and for tumors larger than 5 cm, 28.57%. Five-year survival rate was 64.28% if no lymph nodes were involved, 21.43% if there were unilateral metastatic lymph nodes and 14.28% if bilateral lymph nodes had metastatic disease. Histologic grades of the tumor showed that for grade 1, five-year survival was 64.28%, for grade 2, 35.71% and there were no survivors five years after surgery among patients with grade 3 tumor. CONCLUSION: FIGO stage, size of tumor, lymph node involvement and grade of tumor are significant prognostic factors for survival of patients after surgery.

Leiomyoma of the uterus and retroperitoneal angioleiomyoma: case report.

Retroperitoneal angioleiomyoma is a benign mesenchymal neoplasm that is composed of smooth muscle cells and thick-walled vessels. In a 36-year-old patient a retrouterine and retroperitoneal tumor, 70 x 65 x 50 mm in size, was discovered during a surgical procedure due to uterine myoma. The tumor had a soft consistency and was completely removed. Histopathology showed features of angioleiomyoma. Angioleiomyoma is a rare benign entity; hence a benign course and good prognosis are expected.

[Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon]. / Uspesno lecenje primarne mijelofibroze s trombocitozom u trudnoci primenom alfa-interferona.

Primary myelofibrosis is predominantly a disease of old age, poor prognosis and no curable treatment. Thrombocytosis was observed in only 12% of patients. To our knowledge, there is only one reported case of a young woman with primary myelofibrosis who had a term pregnancy [1]. We report on a 29-year-old woman with thrombocytosis and medical history of two miscarriages in the last 2 years, the iirst at 30 weeks of gestation and the second at 27 weeks. Multiple placental infarctions were observed. She was without symptoms but with moderate splenomegaly 4.5 cm below left costal margin). The platelet count was 651 x 10(9)/L, WBC 7.2 x 10(9)/L with normal differential formula, and haemoglobin level 12 g/dl. Bone marrow biopsy showed fibrotic phase of primary myelofibrosis, with hyperplasia of megacaryocytes, decreased numbers of erythroid and granulocytic cells, and increased amounts of reticulin fibres. Cyctogenetic examination of the bone marrow showed normal female caryotype. Increased numbers of progenitors CFU-Mk, CFU-GM and BFU-E were observed in peripheral blood, and decreased numbers in bone marrow cultures. As the patient wished to become pregnant, the treatment with interferon-a (Roferon A) was started at a dose of 3 MU s.c., three times per week. The platelet count rapidly decreased at a level of 260-370 x 10(9)/L. The pregnancy was diagnosed 5 months later. At the 24 week of pregnancy, platelet count raised to 690 x 10(9)/l and the dose of interferon-a was augmented, 3 MU every day, until delivery. Foetal growth and placental circulation were monitored by serial ultrasonography. At the end of 34 weeks of pregnancy, it was noted that placental flow became insufficient, and after foetal lung maturity was stimulated with dexamethasone, Cesarean section was performed. Male baby was born, weighting 2000 g, with respiratory distress syndrome. This complication was successfully treated, and the child is now one year old, with normal growth and development. The mother is still on therapy with interferon-a, 3 MU, three times a week, and the last blood count was as follows: haemoglobin 10.7 g/dl, WBC 6.1 x 10(9)/L and platelet comt 437 x 10(9)/L. In conclusion, according to the clinical results of interferon-d in thrombocytosis and experimental studies which showed the absence of placental transfer of interferon-d, this therapy could be recommended to women with primary myelofibrosis who wish to have a baby.